Johnson and Johnson Covid-19 Vaccine

The US Food and Drug Administration limits the Johnson & Johnson Covid-19 vaccine and declared it amid the risk of life-threatening blood clots ( Thrombosis with Thrombocytopenia Syndrome). The USFDA said, over 18 million people could have TTS risk. Johnson & Johnson was authorized for emergency use in February 2021. TTS cases begin one or two weeks after vaccination, taking the tally of TTS cases to 60 in March 2022.